Clinigen
Clinigen Group plc, headquartered in the United Kingdom, is a leading global pharmaceutical and services company specialising in the provision of access to medicines. Founded in 2010, Clinigen has rapidly established itself in the healthcare industry, focusing on unlicensed and niche products, clinical trial services, and the management of complex supply chains. With a strong presence in Europe, North America, and Asia, Clinigen offers unique solutions that bridge the gap between pharmaceutical companies and patients. Their core services include the provision of clinical trial supplies and the management of access programmes, ensuring that patients receive critical treatments when they need them most. Clinigen's commitment to patient access and innovative solutions has positioned it as a trusted partner in the global healthcare landscape, achieving significant milestones in expanding its product offerings and market reach.
DitchCarbon Score
How does Clinigen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Clinigen's score of 47 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Clinigen's reported carbon emissions
Clinigen, headquartered in Great Britain, has made significant commitments to reduce its carbon emissions, although specific emissions data is currently unavailable. The company has set ambitious targets to achieve a 42% reduction in absolute greenhouse gas (GHG) emissions across Scope 1 and Scope 2 by 2030, starting from 2022. Additionally, Clinigen aims for a similar 42% reduction in Scope 3 emissions, specifically from air and road freight, within the same timeframe. Looking further ahead, Clinigen has committed to a long-term goal of reducing total GHG emissions across all scopes by 90% by 2040. The company has also set a Net Zero ambition for 2040, aligning with broader industry standards and commitments. Clinigen's targets have been recognised by the Science Based Targets initiative (SBTi), reinforcing its commitment to sustainable practices within the pharmaceuticals, biotechnology, and life sciences sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Clinigen is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
